Research on erythrocyte-liposome drug delivery system for targeted therapy of lung metastatic triple-negative breast cancer

Xiang LI; Xunyi YOU; Xiaocheng LI; Hong WANG; Rui ZHONG; Jiaxin LIU; Limin CHEN; Ye CAO

Return

Research on erythrocyte-liposome drug delivery system for targeted therapy of lung metastatic triple-negative breast cancer

VernacularTitle:红细胞-脂质体药物递送系统靶向治疗三阴性乳腺癌肺转移癌的研究
Author: Xiang LI ¹ ; Xunyi YOU ¹ ; Xiaocheng LI ² ; Hong WANG ¹ ; Rui ZHONG ¹ ; Jiaxin LIU ¹ ; Limin CHEN ¹ ; Ye CAO ¹
Author Information

1. Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610052, China
2. Chengdu University, Chengdu 610106, China
Publication Type:Journal Article
Keywords: paclitaxel; plerixafor; RBC hitchhiking; liposome; tumor-targeted drug delivery system
From: Chinese Journal of Blood Transfusion 2026;39(2):180-187
CountryChina
Language:Chinese
Abstract: Objective: To prepare the erythrocyte-liposome drug delivery system to enhance the therapeutic effect of drugs on tumors and inhibit tumor metastasis. Methods: This study prepared and characterized paclitaxel (PTX)-plerixafor (AMD3100) liposomes (Lips), developed the erythrocyte-liposome drug delivery system, and evaluated its targeting efficiency and therapeutic efficacy through a series of in vitro cellular and in vivo animal experiments. Results: The particle size of PTX-AMD-Lips was (186.4±0.83) nm. Drug encapsulation efficiency of PTX-AMD-Lips was (75.50±5.27)% for PTX and (88.31±2.45)% for AMD. The Binding efficiency between RBC and liposomes in the drug delivery system was (69.93±2.55)%. Vitro cellular experiments revealed that PTX-AMD-Lips significantly inhibited tumor cell migration. In vivo animal experiments, the erythrocyte-liposome drug delivery system significantly increased drug accumulation in the lungs. At the experimental endpoint, the quantitative fluorescence signal of tumor size measured (4.04±0.44)×10 for the PTX-Lips group, and (5.14±3.40)×10 for the RBC-PTX-AMD-Lips group. Conclusion: The erythrocyte-liposome drug delivery system could enhance the lung-specific targeting capability of liposomes, kill tumor cells and suppress further metastasis effectively.